

**Table 2:** 2026 Clinical and Laboratory Standards Institute Susceptible Breakpoints for Select Gram-Negative Organisms and Antibiotic Combinations as Suggested in the 2026 IDSA AMR Guidance Document<sup>1</sup>

| Antibiotic                     | Enterobacterales<br>(µg/mL) | <i>Pseudomonas<br/>aeruginosa</i><br>(µg/mL) | Carbapenem-<br>Resistant<br><i>Acinetobacter<br/>baumannii</i><br>(µg/mL) | <i>Stenotrophomonas<br/>maltophilia</i><br>(µg/mL) |
|--------------------------------|-----------------------------|----------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------|
| Amikacin                       | ≤4                          | ≤16 <sup>2</sup>                             | --                                                                        | --                                                 |
| Ampicillin-sulbactam           | --                          | --                                           | ≤8/4                                                                      | --                                                 |
| Aztreonam                      | ≤4                          | ≤8                                           | --                                                                        | --                                                 |
| Aztreonam-avibactam            | ≤4/4                        | --                                           | --                                                                        | -- <sup>3</sup>                                    |
| Cefepime                       | ≤2 <sup>4</sup>             | ≤8                                           | --                                                                        | --                                                 |
| Cefepime-enmetazobactam        | ≤8/8 <sup>5</sup>           | --                                           | --                                                                        | --                                                 |
| Cefiderocol                    | ≤4                          | ≤4                                           | ≤4                                                                        | ≤1                                                 |
| Ceftazidime                    | ≤4                          | ≤8                                           | --                                                                        | --                                                 |
| Ceftazidime-avibactam          | ≤8/4                        | ≤8/4                                         | --                                                                        | --                                                 |
| Ceftolozane-tazobactam         | ≤2/4                        | ≤4/4                                         | --                                                                        | --                                                 |
| Ciprofloxacin                  | ≤0.25                       | ≤0.5                                         | --                                                                        | --                                                 |
| Colistin or polymyxin B        | -- <sup>6</sup>             | -- <sup>6</sup>                              | -- <sup>6</sup>                                                           | --                                                 |
| Ertapenem                      | ≤0.5                        | --                                           | --                                                                        | --                                                 |
| Fosfomycin (intravenous)       | ≤8 <sup>5,7</sup>           |                                              |                                                                           |                                                    |
| Fosfomycin tromethamine (oral) | ≤64 <sup>8</sup>            | --                                           | --                                                                        | --                                                 |
| Gentamicin                     | ≤2                          | --                                           | --                                                                        | --                                                 |
| Gepotidacin                    | ≤16 <sup>2,5</sup>          | --                                           | --                                                                        | --                                                 |
| Imipenem                       | ≤1                          | ≤2                                           | --                                                                        | --                                                 |
| Imipenem-relebactam            | ≤1/4                        | ≤2/4                                         | --                                                                        | --                                                 |
| Levofloxacin                   | ≤0.5                        | ≤1                                           | --                                                                        | ≤2                                                 |
| Meropenem                      | ≤1                          | ≤2                                           | --                                                                        | --                                                 |
| Meropenem-vaborbactam          | ≤4/8                        | --                                           | --                                                                        | --                                                 |
| Minocycline                    | ≤4                          | --                                           | ≤1                                                                        | ≤1                                                 |
| Nitrofurantoin                 | ≤32 <sup>2</sup>            | --                                           | --                                                                        | --                                                 |
| Piperacillin-tazobactam        | ≤8/4 <sup>9</sup>           | ≤16/4                                        | --                                                                        | --                                                 |
| Pivmecillinam (mecillinam)     | ≤8 <sup>2</sup>             | --                                           | --                                                                        | --                                                 |
| Plazomicin                     | ≤2                          | --                                           | --                                                                        | --                                                 |
| Sulbactam-durlobactam          | --                          | --                                           | ≤4/4                                                                      | --                                                 |
| Sulopenem                      | ≤0.25 <sup>5</sup>          | --                                           | --                                                                        | --                                                 |
| Tigecycline                    | ≤2 <sup>5</sup>             | --                                           | --                                                                        | --                                                 |
| Trimethoprim-sulfamethoxazole  | ≤2/38                       | --                                           | --                                                                        | ≤2/38                                              |
| Tobramycin                     | ≤2                          | ≤1                                           | --                                                                        | --                                                 |

<sup>1</sup>For full details of antibiotic susceptibility testing interpretations refer to: Clinical and Laboratory Standards Institute. 2026. M100: Performance Standards for Antimicrobial Susceptibility Testing. 36<sup>th</sup> ed. Wayne, PA. CLSI M100 document is updated annually; susceptibility criteria subject to changes in 2027.

---

<sup>2</sup>Breakpoints only available for urinary tract infections.

<sup>3</sup>Neither CLSI nor FDA breakpoints are available.

<sup>4</sup>Cefepime MICs of 4-8 µg/mL are susceptible dose-dependent.

<sup>5</sup>CLSI breakpoints are not available. FDA breakpoints are listed instead.

<sup>6</sup>No susceptible category for colistin or polymyxin B; MICs ≤2 µg/mL are categorized as intermediate.

<sup>7</sup>The *Escherichia coli* breakpoint is ≤8 µg/mL; the *Klebsiella pneumoniae* breakpoint is ≤32 µg/mL.

<sup>8</sup>Applies to *Escherichia coli* urinary tract isolates only.

<sup>9</sup>Piperacillin-tazobactam MICs of 16/4 µg/mL are susceptible dose-dependent.